{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:07:53Z","timestamp":1779959273657,"version":"3.53.1"},"reference-count":29,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Stage III non-small cell lung cancer (NSCLC) represents a clinically and biologically heterogeneous disease group, posing challenges in treatment standardization. Objective: This study aimed to evaluate survival outcomes and prognostic factors in patients with pathological stage III NSCLC undergoing upfront surgery in a real-world setting. Methods: Patients treated between January 2009 and December 2023 were retrospectively analyzed. All patients underwent anatomical resection with systematic mediastinal lymph node dissection and achieved complete (R0) resection. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan\u2013Meier method, and prognostic factors were evaluated using Cox proportional hazards regression. Nomograms were developed for individualized survival prediction. Results: A total of 390 patients were included, with a median follow-up of 35 months. The median OS was 47 months, and the median RFS was 30 months. Multivariable analysis identified age, PET-detected mediastinal nodal involvement, tumor location, postoperative complications, pathological nodal status, adjuvant chemotherapy, and adjuvant radiotherapy as independent predictors of OS (p = 0.001, p = 0.029, p = 0.006, p =0.002, p = 0.009, and 0.004, respectively), while adjuvant chemotherapy was associated with improved survival (p = 0.010). For RFS, pathological N2b disease, stage IIIB, tumor location, and adenocarcinoma histology were independent predictors (p = 0.001, p = 0.016, p = 0.029, and p = 0.027, respectively). The OS nomogram demonstrated moderate discriminative ability, whereas the RFS model showed limited predictive performance. Conclusions: These findings highlight the substantial heterogeneity of stage III NSCLC and emphasize the importance of individualized, multidisciplinary treatment strategies beyond conventional staging systems.<\/jats:p>","DOI":"10.3390\/curroncol33060316","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:00:36Z","timestamp":1779955236000},"page":"316","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-8088","authenticated-orcid":false,"given":"Bekir","family":"Elma","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal Zehra","family":"Kumbasar","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Alanya Training and Research Hospital, 07400 Antalya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkay","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ulusan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maruf","family":"Sanli","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-3819","authenticated-orcid":false,"given":"Ahmet Ferudun","family":"Isik","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: An update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"108671","DOI":"10.1016\/j.lungcan.2025.108671","article-title":"Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group","volume":"207","author":"Xenophontos","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/ccts-20-65","article-title":"Management of stage IIIA non-small-cell lung cancer: Role of surgery","volume":"3","author":"Iranpour","year":"2021","journal-title":"Curr. Chall. Thorac. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtcvs.2017.10.075","article-title":"Upfront surgery as first-line therapy in selected patients with stage IIIA non\u2013small cell lung cancer","volume":"155","author":"Zheng","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_7","unstructured":"Furrer, K., Weder, W., Eboulet, E.I., Betticher, D., Pless, M., Stupp, R., Krueger, T., Perentes, J.Y., Schmid, R.A., and Lardinois, D. (May, January 30). Extended resection for potentially operable patients with stage III non\u2013small cell lung cancer after induction treatment. Proceedings of the 101st Annual Meeting of the American-Association-for-Thoracic-Surgery\/Aortic Symposium and Mitral Conclave\u2014A Virtual Learning Experience\/Cardiothoracic Ethics Forum on Measuring Surgical Competence\u2014Why, When, How, and What to Do About It, Virtual."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00595-021-02333-2","article-title":"Safe pneumonectomy for locally advanced lung cancer after induction therapy","volume":"52","author":"Go","year":"2021","journal-title":"Surg. Today"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: More than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.21037\/tcr-22-2757","article-title":"Development and validation of a nomogram for predicting overall survival in patients with stage III-N2 lung adenocarcinoma based on the SEER database","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100566","DOI":"10.1016\/j.lanepe.2022.100566","article-title":"Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: A French nationwide study from the Epithor cohort database","volume":"26","author":"Alifano","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s12094-024-03704-0","article-title":"The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: A systematic review and network meta-analysis","volume":"27","author":"Li","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ezae110","DOI":"10.1093\/ejcts\/ezae110","article-title":"Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer","volume":"65","author":"Tian","year":"2024","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jtcvs.2024.02.006","article-title":"Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)","volume":"168","author":"Yang","year":"2024","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.21037\/jtd-24-287","article-title":"Immunotherapy in operable non-small cell lung cancer: A systematic review and network meta-analysis of efficacy between neoadjuvant immunochemotherapy and perioperative immunotherapy","volume":"16","author":"He","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_16","unstructured":"Collaud, S., Provost, B., Besse, B., Fabre, D., Le Chevalier, T., Mercier, O., Mussot, S., and Fadel, E. (2016, January 4\u20137). Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?. Proceedings of the 17th World Conference of the International-Association-for-the-Study-of-Lung-Cancer (IASLC) on Lung Cancer, Vienna, Austria."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2478\/raon-2022-0030","article-title":"Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer","volume":"56","author":"Bitenc","year":"2022","journal-title":"Radiol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100410","DOI":"10.1016\/j.esmoop.2022.100410","article-title":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: An exploratory analysis from the PACIFIC trial","volume":"7","author":"Senan","year":"2022","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2217\/imt-2023-0002","article-title":"Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results","volume":"15","author":"Verschueren","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2020.03.25","article-title":"Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)\u2014A German radiation oncology survey","volume":"9","author":"Eze","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.2169\/internalmedicine.3097-23","article-title":"Real-world Prognostic Data on Unresectable Stage III Non-small-cell Lung Cancer Treated with Concurrent Chemoradiation Therapy by Histological Type","volume":"63","author":"Toriyama","year":"2024","journal-title":"Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.xjon.2020.12.006","article-title":"Mediastinal radiotherapy after adjuvant chemotherapy for resected non-small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis","volume":"5","author":"Harling","year":"2020","journal-title":"JTCVS Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): An open-label, randomised, phase 3 trial","volume":"23","author":"Pourel","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mulita, A., Valsamaki, P., Bekou, E., Anevlavis, S., Nanos, C., Zisimopoulos, A., Giatromanolaki, A., and Koukourakis, M.I. (2025). Benefits from 18F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study. Cancers, 17.","DOI":"10.3390\/cancers17121969"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13014-019-1304-2","article-title":"Initial report on feasibility of PET\/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: A retrospective analysis","volume":"14","author":"Eze","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Shafie, R.E., Willmann, J., Gkika, E., Schimek-Jasch, T., Miederer, M., Bozorgmehr, F., Griesinger, F., Manapov, F., Christopoulos, P., and Hehr, T. (2026). FDG-PET\/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO)\u2014A randomized, open-label, multicenter phase II trial protocol. BMC Cancer, 26.","DOI":"10.1186\/s12885-026-15901-x"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108798","DOI":"10.1016\/j.lungcan.2025.108798","article-title":"Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group","volume":"209","author":"Prisciandaro","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00408-021-00447-5","article-title":"Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry","volume":"199","author":"Arndt","year":"2021","journal-title":"Lung"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/316\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:51:41Z","timestamp":1779958301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060316"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060316","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}